Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-09-25
2009-12-22
Kim, Jennifer M (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S304000, C514S423000, C514S642000
Reexamination Certificate
active
07635709
ABSTRACT:
The present disclosure provides compositions and methods for on-going bowel care for persons with chronic intestinal pseudo-obstruction. The compositions and methods can be administered in a non-clinical setting. The compositions comprise acetylcholinesterase inhibitors for stimulating motility of the bowel in combination with anti-cholinergic agents to counteract the potentially dangerous cardiac side effects of the acetylcholinesterase inhibitor. In some examples, the acetylcholinesterase inhibitor, neostigmine, and the anti-cholinergic agent, glycopyrrolate, are combined in a pharmaceutical composition. Certain examples also provide the frequency and duration of administration of the disclosed drug combinations.
REFERENCES:
patent: 5362756 (1994-11-01), Riviere et al.
patent: 6469030 (2002-10-01), Farrar et al.
patent: 0140434 (1985-05-01), None
Vavilala et al. Neostigmine for acute colonic pseudo-obstruction. New England Journal of Medicine, 1999 vol. 341, No. 21, pp. 1622-1623.
Calvet et al., “Repeated Neostigmine Dosage as Palliative Treatment for Chronic Colonic Pseudo-Obstruction in a Patient with Autonomic Paraneoplastic Neuropathy,”The American Journal of Gastroenterology, vol. 98, No. 3, pp. 708-709, 2003.
Child, “Glycopyrrolate and the Bowel,”Anaesthesia, vol. 39, No. 5, pp. 495-496, 1984.
Child, “Prevention of Neostigmine-Induced Colonic Activity,”Anaethesia, vol. 39, pp. 1083-1085, 1984.
Fajardo, et al., “Decreased Colonic Motility in Persons With Chronic Spinal Cord Injury.”The American Journal of Gastroenterology, vol. 98, No. 1, pp. 128-134, 2003.
Mehan et al., “Comparison of Recovery in Patients Receiving Atropine-Neostigmine or Glycopyrrolate-Neostigmine for Reversal of Neuromuscular Block,”Ind. J. Anaesth., vol. 38, pp. 234-238, 1990.
Ponec et al., “Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction,”The New England Journal of Medicine, vol. 341, No. 3, pp. 137-141, 1999.
Korsten et al., “Infusion of Neostigmine-Glycopyrrolate for Bowel Evacuation in Persons with Spinal Cord Injury,”Am. J. Gastroenterology, 100:1560-1565, 2005.
Nelson and Fine, “Bowel Elimination and Continence,” Nursing Practice Related to Spinal Cord Injury and Disorders: A Core Curriculum, A. Nelson (Ed.), Eastern Paralyzed Veterans Association, Palo Alto, CA, pp. 203-223, 2001.
Stiens et al., “Neurogenic Bowel Dysfunction After Spinal Cord Injury: Clinical Evaluation and Rehabilitative Management,”Arch. Phys. Med. Rehabil., 78:S86-S104, 1997.
Stiens et al., “The Gastrointestinal System after Spinal Cord Injury,” Spinal Cord Medicine Principles and Practice, V.W. Lin (Ed.), New York, NY, pp. 321-348, 2003.
“Neurogenic Bowel Management in Adults with Spinal Cord Injury,” Clinical Practice Guidelines, Spinal Cord Medicine, Consortium for Spinal Cord Medicine, Paralyzed Veterans of America, pp. 1-39, Mar. 1998.
Bauman William A.
Korsten Mark
Kim Jennifer M
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
LandOfFree
Compositions and methods for bowel care in individuals with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for bowel care in individuals with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for bowel care in individuals with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074423